Item 2.02 Results of Operations and Financial Condition
On January 9, 2023, Anebulo Pharmaceuticals, Inc. (the "Company") announced in
its corporate presentation that as of December 31, 2022 it had $16 million in
cash which is expected to provide a cash runway into 2024.
The information in this Item 2.02 of this Current Report on 8-K is furnished and
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or subject to the liabilities of that section
or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The
information shall not be deemed incorporated by reference into any other filing
with the Securities and Exchange Commission made by the Company, whether made
before or after today's date, regardless of any general incorporation language
in such filing, except as shall be expressly set forth by specific references in
such filing.
Item 7.01 Regulation FD Disclosure.
On January 9, 2023, the Company updated its corporate slide presentation for use
in meetings with investors, analysts and others. The presentation is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference
herein.
The information in this Item 7.01 of this Current Report on 8-K (including
Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the
liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended. The information shall not be deemed incorporated by reference
into any other filing with the Securities and Exchange Commission made by the
Company, whether made before or after today's date, regardless of any general
incorporation language in such filing, except as shall be expressly set forth by
specific references in such filing.
Item 8.01 Other Events.
On January 9, 2023, the Company issued a press release titled, "Anebulo
Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B
of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication." The press
release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is
incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number Description
99.1 Company Presentation dated January 2023
Press Release of Anebulo Pharmaceuticals, Inc., dated January 9,
99.2 2023
Cover Page of Interactive Data File (embedded within the Inline XBRL
104 document).
© Edgar Online, source Glimpses